Biosensia appoints James D. Merselis as Non-Executive Director
BiosensiaLtd, a point of care diagnostics company, based at NovaUCD, the Centre for New Ventures and Entrepreneurs, today announced the appointment of James D. Merselis as Non-Executive Director.
Jim is currently a non-executive director at Trinity Biotech (NASDAQ: TRIB) and a consultant to healthcare diagnostics companies.
He was formerly President and CEO of ITC Nexus Dx, Inc, a privately held diagnostics company working to improve patient care by providing rapid and reliable point of care medical test information. Prior to this, he served as President and CEO of Alverix, Inc, a privately held company developing portable medical diagnostic instruments.
James D. Merselis
Previous roles included, President and CEO of HemoSense Inc, (AMEX: HEM), President and CEO of Micronics, and a number of positions with Boehringer Mannheim Diagnostics (now Roche Diagnostics).
Diarmuid Flavin, CEO of Biosensia, said, "Jim will make an excellent addition to the board at Biosensia. He has a wealth of experience in the diagnostics and point of care in particular and as we progress towards the commercialisation of RapiPlex, his skills and experience will be invaluable.”
Jim Merselis said, “I am very pleased to be joining Biosensia at this exciting time. The company has developed an excellent product with RapiPlex, and I look forward to helping steer the company to success in the point of care market.”
Over the past year Biosensia has hit a number of important milestones. The company raised €1.2 million in November 2011 and in July 2012 the company showcased the RapiPlex platform for the first time at the American Association for Clinical Chemistry’s(AACC) annual meeting.
ENDS
23 October 2012
For further information contact Micéal Whelan, University College Dublin, Communications Manager (Innovation), t: + 353 1 716 3712, e: miceal.whelan@ucd.ieor Tony Stephenson, e: anthonytstephenson@gmail.com.
Editors Notes
Biosensia is an in vitro diagnostics company, focused on developing next generation point of care (POC) technology with a broad range of applications. Biosensia has developed RapiPlex, a rapid, novel, multiplexing POC in vitro diagnostics platform, which can be used for a wide range of diagnostic applications. RapiPlex is suitable for use in all immunoassay formats and for multiple POC applications including medical, environmental, food safety and security. RapiPlex is suitable for use with a variety of small and large sample sizes and types including whole blood, serum, plasma, saliva and urine. Biosensia collaborates with healthcare companies to develop point of care diagnostics products. Biosensia is an independent, venture capital funded company. www.biosensia.com
At NovaUCD, the hub for new ventures and entrepreneurs at University College Dublin, we provide purpose-built, state-of-the-art incubation facilities for knowledge-intensive companies alongside a comprehensive business support programme for our client companies. At NovaUCD we nurture new technology and knowledge-intensive enterprises such as Biosensia. NovaUCD has been funded through a unique public-private partnership that includes AIB Bank, Arthur Cox, Deloitte, Enterprise Ireland, Ericsson, Goodbody Stockbrokers, UCD and Xilinx. www.ucd.ie/innovation
